Dalbavancin Promising in Diabetes-Related Foot Osteomyelitis

A recent study finds the potential of the antibiotic dalbavancin in managing diabetes-related foot osteomyelitis, a severe complication affecting patients with diabetes. The findings were published in journal of Infectious Diseases Now.

A total of thirteen patients were included from January 2019 to December 2021, a substantial 85% underwent surgical treatment, underlining the severity of the cases involved. Also, this research encompassed consecutive patients receiving at least one 1500 mg dose of dalbavancin. Dalbavancin was administered as the first-line treatment in 46% of the cases, while 54% received it as a second-line option, required by adverse events linked to prior treatments.

The study reported just one adverse event, highlighting the overall well-tolerated nature of dalbavancin. After a rigorous 6-month follow-up period from the last dalbavancin dose, the findings revealed that 82% of the evaluable patients achieved remission. Remission was defined as the absence of relapsing infection or the need for surgery at the initial or a contiguous site.

These promising results suggest that dalbavancin holds potential as an effective and safe treatment option for diabetes-related foot osteomyelitis, especially when considering its favorable tolerability and notable efficacy in both microbiological and clinical aspects.